Quantum-Si Inc is expected to report a Q3 2026 consensus revenue of $0.27 million and an EPS loss of $0.13, while its stock currently trades at $1.72 compared to a $2.50 analyst price target.
Investors are primarily focused on management’s update regarding the Proteus platform development and its transition toward a full commercial launch in early 2027.
The company recently achieved a key technical milestone by detecting 19 of the 20 standard amino acids, fueling optimism for its next-generation protein sequencing capabilities. Management has characterized 2026 as a deliberate transition year, utilizing its extended cash runway to support instrument upgrade programs while maintaining liquidity through late 2028.